Mozobil® (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration
{{output}}
AMD3100 (plerixafor, Mozobil®) was first identified as an anti-HIV agent specifically active against the T4-lymphotropic HIV strains, as it selectively blocked the CXCR4 receptor. Through interference with the interaction of CXCR4 with its natural ligand, SDF... ...
